During the past decade, H.-Hartziekenhuis Roeselare-Menen vzw conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 13 clinical trials were completed, i.e. on average, 325% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "H.-Hartziekenhuis Roeselare-Menen vzw" #1 sponsor was "Pfizer" with 10 trials, followed by "Celgene" with 5 trials sponsored, "Boston Scientific Corporation" with 2 trials sponsored, "Shire" with 2 trials sponsored and "Bavarian Nordic" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "H.-Hartziekenhuis Roeselare-Menen vzw" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator, "Pharmaceutical Research Associates" with 1 trials as a collaborator and "The Leukemia and Lymphoma Society" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "H.-Hartziekenhuis Roeselare-Menen vzw" are "Ulcerative Colitis" (6 trials), "Alzheimer Disease" (3 trials), "Myelodysplastic Syndromes" (2 trials), "Abdominal Aortic Aneurysms (AAA)" (1 trials) and "Acute Myeloid Leukemia" (1 trials). Many other conditions were trialed in "H.-Hartziekenhuis Roeselare-Menen vzw" in a lesser frequency.

Most popular intervention types in "H.-Hartziekenhuis Roeselare-Menen vzw" are "Drug" (22 trials), "Biological" (2 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Rituximab" (3 trials), "CP-690,550" (2 trials), "Gemcitabine" (2 trials) and "bapineuzumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "H.-Hartziekenhuis Roeselare-Menen vzw" are 24 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "H.-Hartziekenhuis Roeselare-Menen vzw". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in H.-Hartziekenhuis Roeselare-Menen vzw, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in H.-Hartziekenhuis Roeselare-Menen vzw, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".